Status:

COMPLETED

Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women

Lead Sponsor:

University of KwaZulu

Collaborating Sponsors:

Bristol-Myers Squibb

Conditions:

Puerperal Sepsis

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Postpartum infections are among the leading causes of maternal mortality world-wide, particularly in under-resourced countries. Available data suggests that HIV infected women are at greater risk of p...

Detailed Description

INTRODUCTION The World Health Organisation (WHO) estimates that 582 000 women die world-wide each year due to pregnancy related conditions that could be prevented. Most of these deaths occur in develo...

Eligibility Criteria

Inclusion

  • Women with a pregnancy of \> to 36 weeks of gestation
  • Women with known HIV status as documented by routine rapid HIV tests, following pre-test voluntary counselling and testing (VCT).
  • Women who gave informed study consent.
  • Over the age of 18years
  • Eligible for vaginal delivery

Exclusion

  • Women who received antibiotic therapy less than 2 weeks prior to study enrolment.
  • Women planned for elective caesarean delivery.
  • Obstetric complications such as preterm prelabour rupture of membranes, cardiac disease, diabetes and antepartum haemorrhage.

Key Trial Info

Start Date :

February 1 2003

Trial Type :

INTERVENTIONAL

End Date :

May 1 2005

Estimated Enrollment :

1372 Patients enrolled

Trial Details

Trial ID

NCT00343317

Start Date

February 1 2003

End Date

May 1 2005

Last Update

June 22 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of KwaZulu-Natal / King Edward VIII Hospital

Durban, KwaZulu-Natal, South Africa, 4013